Skip to main content
logo
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.8620
+0.0199 (2.36%)
Feb 6, 2026, 4:00 PM EST - Market closed

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
---0.050.45-
Revenue Growth (YoY)
----89.98%--
Cost of Revenue
---0.010.09-
Gross Profit
---0.030.36-
Selling, General & Admin
10.6112.915.9815.96.163.59
Research & Development
9.198.8813.017.263.83.18
Operating Expenses
19.821.7828.9923.169.966.77
Operating Income
-19.8-21.78-28.99-23.13-9.61-6.77
Interest Expense
-0.34-0.93-1.07-0.16-0.61-0.16
Other Non Operating Income (Expenses)
0.010.511.33-2.130.24-1.05
EBT Excluding Unusual Items
-20.13-22.2-28.73-25.42-9.98-7.99
Other Unusual Items
---0.47--0.060.06
Pretax Income
-20.13-22.2-29.2-25.42-10.92-7.93
Income Tax Expense
0.020.010.020.010.010
Earnings From Continuing Operations
-20.15-22.21-29.22-25.43-10.93-7.94
Minority Interest in Earnings
0.210.07----
Net Income
-19.95-22.14-29.22-25.43-10.93-7.94
Preferred Dividends & Other Adjustments
5.671.67----
Net Income to Common
-25.62-23.81-29.22-25.43-10.93-7.94
Shares Outstanding (Basic)
310000
Shares Outstanding (Diluted)
310000
Shares Change (YoY)
571.35%374.79%98.24%-56.93%15.26%-
EPS (Basic)
-9.02-35.70-207.95-358.77-66.44-55.59
EPS (Diluted)
-9.02-35.70-207.95-358.77-66.44-55.59
Free Cash Flow
-21.77-19.71-27.57-13.64-7.98-5.18
Free Cash Flow Per Share
-7.67-29.55-196.22-192.49-48.49-36.26
Gross Margin
---68.89%79.06%-
Operating Margin
----51395.56%-2139.42%-
Profit Margin
----56504.44%-2434.97%-
Free Cash Flow Margin
----30315.56%-1777.28%-
EBITDA
-19.31-21.37-28.6-22.87-9.45-6.67
D&A For EBITDA
0.490.40.390.260.160.11
EBIT
-19.8-21.78-28.99-23.13-9.61-6.77
Revenue as Reported
---0.05--
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q